Can antidepressants unlock prescription of rimonabant in the fight against COVID-19?
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cellular and Molecular Neuroscience,Psychiatry and Mental health,Molecular Biology
Link
http://www.nature.com/articles/s41380-021-01221-y.pdf
Reference11 articles.
1. Hoertel N, Sánchez-Rico M, Vernet R, Beeker N, Jannot AS, Neuraz A, et al. Association between antidepressant use and reduced risk of intubation or death in hospitalized patients with COVID-19: results from an observational study. Mol Psychiatry. 2021. https://doi.org/10.1038/s41380-021-01021-4.
2. Lenze EJ, Mattar C, Zorumski CF, Stevens A, Schweiger J, Nicol GE, et al. Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial. JAMA. 2020;324:2292–2300.
3. Briand-Mésange F, Trudel S, Salles J, Ausseil J, Salles JP, Chap H. Possible role of adipose tissue and the endocannabinoid system in coronavirus disease 2019 pathogenesis: can rimonabant return? Obesity. 2020;28:1580–1.
4. Cinar R, Iyer MR, Kunos G. Dual inhibition of CB1 receptors and iNOS, as a potential novel approach to the pharmacological management of acute and long COVID-19. Br J Pharmacol. 2021. https://doi.org/10.1111/bph.15461.
5. Carpinteiro A, Edwards MJ, Hoffmann M, Kochs G, Gripp B, Weigang S, et al. Pharmacological inhibition of acid sphingomyelinase prevents uptake of SARS-CoV-2 by epithelial cells. Cell Rep Med. 2020;1:100142.
Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Advanced oxidation processes for degradation of pharmaceuticals used during COVID-19 pandemic;Sustainable Technologies for Remediation of Emerging Pollutants from Aqueous Environment;2024
2. COVID-19-Related Mortality Risk in People With Severe Mental Illness: A Systematic and Critical Review;Frontiers in Psychiatry;2022-01-13
3. Repurposing antidepressants inhibiting the sphingomyelinase acid/ceramide system against COVID-19: current evidence and potential mechanisms;Molecular Psychiatry;2021-08-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3